GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » Dividend Payout Ratio

Daiichinkyo Co (STU:D4S) Dividend Payout Ratio : 0.93 (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Daiichinkyo Co's Dividend Payout Ratio for the months ended in Sep. 2024 was 0.93.

The historical rank and industry rank for Daiichinkyo Co's Dividend Payout Ratio or its related term are showing as below:

STU:D4S' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.35   Med: 0.61   Max: 0.91
Current: 0.46


During the past 13 years, the highest Dividend Payout Ratio of Daiichinkyo Co was 0.91. The lowest was 0.35. And the median was 0.61.

STU:D4S's Dividend Payout Ratio is ranked worse than
62.01% of 437 companies
in the Drug Manufacturers industry
Industry Median: 0.37 vs STU:D4S: 0.46

As of today (2024-12-13), the Dividend Yield % of Daiichinkyo Co is 1.30%.

During the past 13 years, the highest Trailing Annual Dividend Yield of Daiichinkyo Co was 3.81%. The lowest was 0.60%. And the median was 1.13%.

Daiichinkyo Co's Dividends per Share for the months ended in Sep. 2024 was €0.19.

During the past 12 months, Daiichinkyo Co's average Dividends Per Share Growth Rate was 71.40% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 22.80% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 13.90% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 7.00% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Daiichinkyo Co was 67.10% per year. The lowest was -9.10% per year. And the median was 5.15% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Daiichinkyo Co Dividend Payout Ratio Historical Data

The historical data trend for Daiichinkyo Co's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Dividend Payout Ratio Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.69 0.78 0.53 0.48

Daiichinkyo Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 - 1.55 - 0.93

Competitive Comparison of Daiichinkyo Co's Dividend Payout Ratio

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Dividend Payout Ratio falls into.



Daiichinkyo Co Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Daiichinkyo Co's Dividend Payout Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Mar. 2024 )/ EPS without NRI (A: Mar. 2024 )
=0.307/ 0.642
=0.48

Daiichinkyo Co's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Sep. 2024 )/ EPS without NRI (Q: Sep. 2024 )
=0.189/ 0.203
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co (STU:D4S) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Daiichinkyo Co Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co Headlines

No Headlines